{"created":"2023-05-15T14:53:26.070932+00:00","id":72766,"links":{},"metadata":{"_buckets":{"deposit":"5fd75d19-44e9-48a9-a620-ef0c7eefa55e"},"_deposit":{"created_by":1,"id":"72766","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"72766"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00072766","sets":["10:28"]},"author_link":["716776","716770","716775","716778","716768","716771","716769","716773","716767","716777","716774","716772"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2018-04-23","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background / Aims: We have developed meta-[211At]astato-benzylguanidine (MABG) for targeted alpha-radionuclide therapy of malignant pheochromocytoma and shown its high antitumor effects in tumor-bearing mice. However, body weight loss, an indicator of toxicity, was transiently observed at therapeutic dose. In this study, we investigated for alleviation of toxicity whether non-specific uptake of MABG could be reduced by inhibiting organic cation transporter (OCT). \nMethods: The uptake of MABG was examined using the following cell lines, PC-12, rat pheochromocytoma, HT-29, human colorectal adenocarcinoma, ACHN, human renal cell adenocarcinoma, BxPC-3, human pancreatic adenocarcinoma. To inhibit OCT, cells were treated with phenoxybenzamine (POB), an inhibitor of OCT1-3, ranitidine (RAN), an inhibitor of OCT1, or hydrocortisone (HDC), an inhibitor of OCT3. \nResults: POB (3 μM), RAN (100 μM) and HDC (10 μM) significantly reduced the uptake of MABG in HT-29, ACHN and BxPC-3. While, the uptake of MABG in PC-12 was slightly inhibited by treatment with POB, but not RAN and HDC. These results indicate that OCT1 and OCT3 were involved in the uptake of MABG in HT-29, ACHN and BxPC-3, but not in PC-12. Therefore, RAN or HDC possibly inhibit the non-specific uptake of MABG in colon, kidney and pancreas. Dose-response study showed that the inhibitory effect of RAN and HDC in HT-29, ACHN and BxPC-3 was enhanced dose-dependently. However, high-dose of RAN (1000 μM), but not HDC (100 μM), reduced the uptake of MABG in PC-12. These results suggest that HDC can inhibit the nonspecific uptake of MABG more selectively.\nConclusion: Our results showed that the non-specific uptake of MABG is possibly reduced by inhibiting OCT1 and OCT3. Furthermore, HDC is a clinically approved drug, and can be a selective inhibitor for reducing non-specific uptake of MABG. At present, we are investigating the usefulness of HDC in tumor-bearing mice.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"12th World Congress of The World Federation of Nuclear Medicine and Biology (WFNMB2018)","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"大島, 康宏"}],"nameIdentifiers":[{"nameIdentifier":"716767","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"渡辺, 茂樹"}],"nameIdentifiers":[{"nameIdentifier":"716768","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"坂下, 哲哉"}],"nameIdentifiers":[{"nameIdentifier":"716769","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"佐々木, 一郎"}],"nameIdentifiers":[{"nameIdentifier":"716770","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"東, 達也"}],"nameIdentifiers":[{"nameIdentifier":"716771","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"石岡, 典子"}],"nameIdentifiers":[{"nameIdentifier":"716772","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"大島 康宏","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"716773","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"渡辺 茂樹","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"716774","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"坂下 哲哉","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"716775","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"佐々木 一郎","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"716776","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"東 達也","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"716777","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"石岡 典子","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"716778","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Inhibition of organic cation transporter reduces non-specific uptake of MABG","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Inhibition of organic cation transporter reduces non-specific uptake of MABG"}]},"item_type_id":"10005","owner":"1","path":["28"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-05-01"},"publish_date":"2018-05-01","publish_status":"0","recid":"72766","relation_version_is_last":true,"title":["Inhibition of organic cation transporter reduces non-specific uptake of MABG"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T19:36:18.295593+00:00"}